Project Grant R43DK108606

This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports the development of a therapeutic nucleic acid vaccine for chronic hepatitis B (CHB) in HIV/HBV co-infected individuals. The award recipient, Orlance, Inc., a woman-owned small business based in Seattle, WA, is leveraging its proprietary MACH-1 gene gun technology to efficiently deliver DNA and...

The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $258,750 Project Grant to HBVTech, L.L.C., a minority-owned small disadvantaged business in Germantown, Maryland. The grant, awarded on September 1, 2025, with an ultimate completion date of August 31, 2026, supports the development of HBVZ10, a new gene therapy candidate for treating chronic hepatitis B virus (HBV) infections. The...

The Department of the Army Medical Command awarded Invvax, Inc. a $1,878,970 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research titled "Invariance Mapping of the Complete HBV Genome and Testing of MRE11 Repair Nuclease Toward the Improvement of CRISPR/Cas Therapy for Hepatitis B." The period of performance is from September 1, 2022 to August 31, 2026. Under this award, Invvax will conduct research to map the complete genome of...

This Project Grant awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) provides $4,728,039.00 to support Hbvtech, L.L.C., a minority-owned small disadvantaged business located in Germantown, Maryland, in developing a novel HBV cure treatment regimen focused on the durable elimination of HBV covalently closed circular DNA (cccDNA) in chronic hepatitis B infections. The funding, awarded on July 1, 2025, supports Hbvtech's research...

This federal Project Grant award of $320,863 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports the translational development of a small molecule therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The project aims to validate the proposed drug target, the hepatitis B X regulatory protein (HBx), which plays a critical role in HBV covalently closed...

Hbvtech received a $279,854 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support Hbvtech's research from May 2021 through April 2023 to develop a novel hepatitis B virus drug aimed at effectively curing chronic hepatitis B. The Military Medical Research and Development program seeks to transform military and public health through innovative medical research solutions,...

This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...

The U.S. National Cancer Institute awarded Gigamune, Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel lentiviral vector technology for enhanced in vivo delivery of T cell receptors for cell therapy to treat Stage IV melanoma. The project aims to address the high costs, manufacturing time, and limited patient access associated with current autologous T cell receptor therapies for late-stage melanoma. Gigamune, Inc. is a San Francisco-based...

The federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,480,488 to Brigham & Women's Hospital Inc. to research the combination of mRNA nanotherapy with standard antiangiogenic/immunotherapy for hepatocellular carcinoma (HCC). The research project runs from September 1, 2023 to August 31, 2026. As part of this effort, Massachusetts General Hospital will conduct preclinical studies to evaluate the...